• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bendamustine supercharge plus brentuximab vedotin as early salvage therapy following failure to obtain complete metabolic remission after two cycles of adriamycin-bleomycin-vinblastine-dacarbazine for classic Hodgkin lymphoma in patients aged ≤ 60 years: Long-term efficacy results of a retrospective multicentre study.

作者信息

Giordano C, Picardi M, Pugliese N, Vincenzi A, Avilia S, De Fazio L, Lamagna M, Reina R, Scarpa A, Lombardi A, Vigliar E, Troncone G, Mascolo M, Mainolfi C, Fonti R, Del Vecchio S, Damiano V, Bianco R, Trastulli F, Annunziata M, Salemme A, Carchia M, Pane F

机构信息

Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy.

Department of Public Health, Federico II University Medical School Naples, Naples, Italy.

出版信息

Br J Haematol. 2025 May;206(5):1502-1507. doi: 10.1111/bjh.20053. Epub 2025 Apr 2.

DOI:10.1111/bjh.20053
PMID:40176291
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12078852/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ba2/12078852/96f1980482c2/BJH-206-1502-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ba2/12078852/07ad95cb170f/BJH-206-1502-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ba2/12078852/96f1980482c2/BJH-206-1502-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ba2/12078852/07ad95cb170f/BJH-206-1502-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ba2/12078852/96f1980482c2/BJH-206-1502-g001.jpg

相似文献

1
Bendamustine supercharge plus brentuximab vedotin as early salvage therapy following failure to obtain complete metabolic remission after two cycles of adriamycin-bleomycin-vinblastine-dacarbazine for classic Hodgkin lymphoma in patients aged ≤ 60 years: Long-term efficacy results of a retrospective multicentre study.对于年龄≤60岁的经典型霍奇金淋巴瘤患者，在接受两个周期的阿霉素-博来霉素-长春花碱-达卡巴嗪治疗后未获得完全代谢缓解时，苯达莫司汀强化联合 Brentuximab vedotin 作为早期挽救治疗：一项回顾性多中心研究的长期疗效结果。
Br J Haematol. 2025 May;206(5):1502-1507. doi: 10.1111/bjh.20053. Epub 2025 Apr 2.
2
Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.自体造血干细胞移植后博纳吐珠单抗联合纳武利尤单抗治疗高危经典型霍奇金淋巴瘤成人患者的多中心、2 期临床试验。
Lancet Haematol. 2023 Jan;10(1):e14-e23. doi: 10.1016/S2352-3026(22)00318-0. Epub 2022 Nov 17.
3
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.本妥昔单抗维迪西妥单抗联合苯达莫司汀治疗复发或难治性霍奇金淋巴瘤的国际多中心单臂 1/2 期临床试验。
Lancet Oncol. 2018 Feb;19(2):257-266. doi: 10.1016/S1470-2045(17)30912-9. Epub 2017 Dec 21.
4
Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.本妥昔单抗联合纳武利尤单抗用于老年或不符合化疗条件的霍奇金淋巴瘤患者的一线治疗（ACCRU）：一项多中心、单臂、2期试验
Lancet Haematol. 2020 Nov;7(11):e808-e815. doi: 10.1016/S2352-3026(20)30275-1. Epub 2020 Oct 1.
5
Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.原发性难治性或复发性经典霍奇金淋巴瘤患者应用本妥昔单抗维泊妥珠单抗联合苯达莫司汀桥接自体造血干细胞移植的真实世界疗效。
Ann Hematol. 2020 Oct;99(10):2385-2392. doi: 10.1007/s00277-020-04204-1. Epub 2020 Aug 3.
6
Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.复发/难治性霍奇金淋巴瘤自体移植前，以本妥昔单抗作为二线治疗的多中心II期试验结果。
Biol Blood Marrow Transplant. 2015 Dec;21(12):2136-2140. doi: 10.1016/j.bbmt.2015.07.018. Epub 2015 Jul 26.
7
Combination of Brentuximab Vedotin and Pembrolizumab as Salvage Treatment Before Autologous Stem Cell Transplantation and Maintenance in Patients with Relapsed/Refractory Hodgkin Lymphoma.在复发/难治性霍奇金淋巴瘤患者中，将维布妥昔单抗与帕博利珠单抗联合用于自体干细胞移植前的挽救治疗及维持治疗。
Biomedicines. 2025 Jan 21;13(2):252. doi: 10.3390/biomedicines13020252.
8
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.本妥昔单抗维迪昔联合 ABVD 或 AVD 方案用于治疗初诊霍奇金淋巴瘤患者的 1 期、开放标签、剂量递增研究。
Lancet Oncol. 2013 Dec;14(13):1348-56. doi: 10.1016/S1470-2045(13)70501-1. Epub 2013 Nov 15.
9
Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy.使用维布妥昔单抗联合放射治疗的经典型霍奇金淋巴瘤患者达到近完全缓解
Case Rep Oncol. 2017 Sep 6;10(3):795-801. doi: 10.1159/000479224. eCollection 2017 Sep-Dec.
10
A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.在干细胞移植前后，对经过大量治疗的难治性或复发性儿童霍奇金淋巴瘤患者采用维布妥昔单抗进行靶向挽救治疗。
Turk J Pediatr. 2019;61(5):671-676. doi: 10.24953/turkjped.2019.05.005.

本文引用的文献

1
Outcome of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma after Different Numbers of Salvage Regimens.不同挽救治疗方案后复发/难治性霍奇金淋巴瘤患者接受高剂量化疗联合自体造血干细胞移植的结局。
Cells. 2024 Jan 9;13(2):118. doi: 10.3390/cells13020118.
2
Comment on "Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.".对“将本妥昔单抗与地塞米松、大剂量阿糖胞苷和顺铂联合用于复发或难治性霍奇金淋巴瘤的挽救治疗：II期HOVON/LLPC移植BRAVE研究”的评论。
Haematologica. 2021 Apr 1;106(4):1226-1227. doi: 10.3324/haematol.2020.278203.
3
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma.
BEGEV挽救方案用于复发/难治性经典型霍奇金淋巴瘤的五年结果
Blood Adv. 2020 Jan 14;4(1):136-140. doi: 10.1182/bloodadvances.2019000984.
4
First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi.贝达珠单抗和本妥昔单抗治疗霍奇金淋巴瘤的首次挽救治疗：意大利淋巴瘤基金会的 2 期研究。
Blood Cancer J. 2019 Dec 11;9(12):100. doi: 10.1038/s41408-019-0265-x.
5
Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma.Brentuximab vedotin 序贯泊马度胺超剂量治疗难治或复发霍奇金淋巴瘤。
Blood Adv. 2019 May 14;3(9):1546-1552. doi: 10.1182/bloodadvances.2019000123.
6
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.本妥昔单抗维迪西妥单抗联合苯达莫司汀：复发或难治性霍奇金淋巴瘤的高效一线挽救治疗方案。
Blood. 2018 Jul 5;132(1):40-48. doi: 10.1182/blood-2017-11-815183. Epub 2018 Apr 27.
7
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.本妥昔单抗维迪西妥单抗联合苯达莫司汀治疗复发或难治性霍奇金淋巴瘤的国际多中心单臂 1/2 期临床试验。
Lancet Oncol. 2018 Feb;19(2):257-266. doi: 10.1016/S1470-2045(17)30912-9. Epub 2017 Dec 21.
8
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.基线代谢肿瘤体积在复发难治性霍奇金淋巴瘤中的预后意义
Blood. 2017 Nov 16;130(20):2196-2203. doi: 10.1182/blood-2017-06-788877. Epub 2017 Sep 5.
9
Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.在化疗难治性霍奇金淋巴瘤患者中，维布妥昔单抗和苯达莫司汀产生了高完全缓解率。
Br J Haematol. 2018 Mar;180(5):757-760. doi: 10.1111/bjh.14449. Epub 2016 Dec 16.
10
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.欧洲药品管理局对用于治疗复发或难治性CD30+霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤成年患者的本妥昔单抗（安适利）的审评：人用药品委员会科学评估总结
Oncologist. 2016 Jan;21(1):102-9. doi: 10.1634/theoncologist.2015-0276. Epub 2015 Nov 30.